|
1
|
La Vecchia C and Boffetta P: Role of
stopping exposure and recent exposure to asbestos in the risk of
mesothelioma. Eur J Cancer Prev. 21:227–230. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Buikhuisen WA, Hiddinga BI, Baas P and van
Meerbeeck JP: Second line therapy in malignant pleural
mesothelioma: A systematic review. Lung Cancer. 89:223–231. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mossman BT, Shukla A, Heintz NH,
Verschraegen CF, Thomas A and Hassan R: New insights into
understanding the mechanisms, pathogenesis, and management of
malignant mesotheliomas. Am J Pathol. 182:1065–1077. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Campbell NP and Kindler HL: Update on
malignant pleural mesothelioma. Semin Respir Crit Care Med.
32:102–110. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Blume-Jensen P and Hunter T: Oncogenic
kinase signalling. Nature. 411:355–365. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maulik G, Shrikhande A, Kijima T, Ma PC,
Morrison PT and Salgia R: Role of the hepatocyte growth factor
receptor, c-Met, in oncogenesis and potential for therapeutic
inhibition. Cytokine Growth Factor Rev. 13:41–59. 2002. View Article : Google Scholar
|
|
7
|
Mukohara T, Civiello G, Davis IJ, Taffaro
ML, Christensen J, Fisher DE, Johnson BE and Jänne PA: Inhibition
of the met receptor in mesothelioma. Clin Cancer Res. 11:8122–8130.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cacciotti P, Libener R, Betta P, Martini
F, Porta C, Procopio A, Strizzi L, Penengo L, Tognon M, Mutti L, et
al: SV40 replication in human mesothelial cells induces HGF/Met
receptor activation: A model for viral-related carcinogenesis of
human malignant mesothelioma. Proc Natl Acad Sci USA.
98:12032–12037. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ramos-Nino ME, Blumen SR, Sabo-Attwood T,
Pass H, Carbone M, Testa JR, Altomare DA and Mossman BT: HGF
mediates cell proliferation of human mesothelioma cells through a
PI3K/MEK5/Fra-1 pathway. Am J Respir Cell Mol Biol. 38:209–217.
2008. View Article : Google Scholar
|
|
10
|
Regan CP, Li W, Boucher DM, Spatz S, Su MS
and Kuida K: Erk5 null mice display multiple extraembryonic
vascular and embryonic cardiovascular defects. Proc Natl Acad Sci
USA. 99:9248–9253. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hayashi M, Kim SW, Imanaka-Yoshida K,
Yoshida T, Abel ED, Eliceiri B, Yang Y, Ulevitch RJ and Lee JD:
Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular
integrity and leads to endothelial failure. J Clin Invest.
113:1138–1148. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Roberts OL, Holmes K, Müller J, Cross DA
and Cross MJ: ERK5 is required for VEGF-mediated survival and
tubular morphogenesis of primary human microvascular endothelial
cells. J Cell Sci. 123:3189–3200. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rovida E, Spinelli E, Sdelci S, Barbetti
V, Morandi A, Giuntoli S and Dello Sbarba P: ERK5/BMK1 is
indispensable for optimal colony-stimulating factor 1
(CSF-1)-induced proliferation in macrophages in a Src-dependent
fashion. J Immunol. 180:4166–4172. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sureban SM, May R, Lightfoot SA, Hoskins
AB, Lerner M, Brackett DJ, Postier RG, Ramanujam R, Mohammed A, Rao
CV, et al: DCAMKL-1 regulates epithelial-mesenchymal transition in
human pancreatic cells through a miR-200a-dependent mechanism.
Cancer Res. 71:2328–2338. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bailey JM, Alsina J, Rasheed ZA,
McAllister FM, Fu YY, Plentz R, Zhang H, Pasricha PJ, Bardeesy N,
Matsui W, et al: DCLK1 marks a morphologically distinct
subpopulation of cells with stem cell properties in preinvasive
pancreatic cancer. Gastroenterology. 146:245–256. 2014. View Article : Google Scholar
|
|
16
|
May R, Riehl TE, Hunt C, Sureban SM, Anant
S and Houchen CW: Identification of a novel putative
gastrointestinal stem cell and adenoma stem cell marker,
doublecortin and CaM kinase-like-1, following radiation injury and
in adenomatous polyposis coli/multiple intestinal neoplasia mice.
Stem Cells. 26:630–637. 2008. View Article : Google Scholar
|
|
17
|
Sureban SM, May R, Qu D, Weygant N,
Chandrakesan P, Ali N, Lightfoot SA, Pantazis P, Rao CV, Postier
RG, et al: DCLK1 regulates pluripotency and angiogenic factors via
microRNA-dependent mechanisms in pancreatic cancer. PLoS One.
8:e739402013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nakanishi Y, Seno H, Fukuoka A, Ueo T,
Yamaga Y, Maruno T, Nakanishi N, Kanda K, Komekado H, Kawada M, et
al: Dclk1 distinguishes between tumor and normal stem cells in the
intestine. Nat Genet. 45:98–103. 2013. View Article : Google Scholar
|
|
19
|
Vega KJ, May R, Sureban SM, Lightfoot SA,
Qu D, Reed A, Weygant N, Ramanujam R, Souza R, Madhoun M, et al:
Identification of the putative intestinal stem cell marker
doublecortin and CaM kinase-like-1 in Barrett's esophagus and
esophageal adenocarcinoma. J Gastroenterol Hepatol. 27:773–780.
2012. View Article : Google Scholar :
|
|
20
|
Sureban SM, May R, Ramalingam S,
Subramaniam D, Natarajan G, Anant S and Houchen CW: Selective
blockade of DCAMKL-1 results in tumor growth arrest by a Let-7a
MicroRNA-dependent mechanism. Gastroenterology. 137:649–659.
659.e641–642. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sureban SM, May R, Mondalek FG, Qu D,
Ponnurangam S, Pantazis P, Anant S, Ramanujam RP and Houchen CW:
Nano-particle-based delivery of siDCAMKL-1 increases microRNA-144
and inhibits colorectal cancer tumor growth via a Notch-1 dependent
mechanism. J Nanobiotechnology. 9:402011. View Article : Google Scholar
|
|
22
|
Ali N, Allam H, May R, Sureban SM, Bronze
MS, Bader T, Umar S, Anant S and Houchen CW: Hepatitis C
virus-induced cancer stem cell-like signatures in cell culture and
murine tumor xenografts. J Virol. 85:12292–12303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li T, Li H, Wang Y, Harvard C, Tan JL, Au
A, Xu Z, Jablons DM and You L: The expression of CXCR4, CXCL12 and
CXCR7 in malignant pleural mesothelioma. J Pathol. 223:519–530.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Varesano S, Salvi S, Boccardo S, Ravetti
JL, Ferro P, Canessa PA, Fedeli F, Pistillo MP and Roncella S:
Amplification of MET in a Patient with Malignant Pleural
Mesothelioma. J Thorac Oncol. 10:e103–e104. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kawakami H, Okamoto I, Okamoto W, Tanizaki
J, Nakagawa K and Nishio K: Targeting MET amplification as a new
oncogenic driver. Cancers (Basel). 6:1540–1552. 2014. View Article : Google Scholar
|
|
26
|
Matsumoto K and Nakamura T: NK4
(HGF-antagonist/angiogenesis inhibitor) in cancer biology and
therapeutics. Cancer Sci. 94:321–327. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Carbone M and Yang H: Molecular pathways:
targeting mechanisms of asbestos and erionite carcinogenesis in
mesothelioma. Clin Cancer Res. 18:598–604. 2012. View Article : Google Scholar
|
|
28
|
Davis IJ, McFadden AW, Zhang Y, Coxon A,
Burgess TL, Wagner AJ and Fisher DE: Identification of the receptor
tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as
therapeutic targets in clear cell sarcoma. Cancer Res. 70:639–645.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kawaguchi K, Murakami H, Taniguchi T,
Fujii M, Kawata S, Fukui T, Kondo Y, Osada H, Usami N, Yokoi K, et
al: Combined inhibition of MET and EGFR suppresses proliferation of
malignant mesothelioma cells. Carcinogenesis. 30:1097–1105. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu X, Newton RC and Scherle PA:
Developing c-MET pathway inhibitors for cancer therapy: Progress
and challenges. Trends Mol Med. 16:37–45. 2010. View Article : Google Scholar
|
|
31
|
Yakes FM, Chen J, Tan J, Yamaguchi K, Shi
Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, et al: Cabozantinib
(XL184), a novel MET and VEGFR2 inhibitor, simultaneously
suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer
Ther. 10:2298–2308. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Trump DL: Commentary on 'Cabozantinib in
patients with advanced prostate cancer: results of a phase II
randomized discontinuation trial'. Smith DC, Smith MR, Sweeney C,
Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark
AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin
CC, Srinivas S, Sella A, SchoffskiSchöffski P, Scheffold C,
Weitzman AL and Hussain M: University of Michigan; Ann Arbor,
MI:
J Clin Oncol. 2013.31(4): 412–9.
View Article : Google Scholar : Epub 2012 Nov 19.
Urol Oncol. 31:18482013. View Article : Google Scholar
|
|
33
|
Dai J, Zhang H, Karatsinides A, Keller JM,
Kozloff KM, Aftab DT, Schimmoller F and Keller ET: Cabozantinib
inhibits prostate cancer growth and prevents tumor-induced bone
lesions. Clin Cancer Res. 20:617–630. 2014. View Article : Google Scholar :
|
|
34
|
Smith DC, Smith MR, Sweeney C, Elfiky AA,
Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon
MS, et al: Cabozantinib in patients with advanced prostate cancer:
Results of a phase II randomized discontinuation trial. J Clin
Oncol. 31:412–419. 2013. View Article : Google Scholar
|
|
35
|
Vaishampayan U: Cabozantinib as a novel
therapy for renal cell carcinoma. Curr Oncol Rep. 15:76–82. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mughal A, Aslam HM, Sheikh A, Khan AM and
Saleem S: c-Met inhibitors. Infect Agent Cancer. 8:132013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
U.S. Food and Drug Administration (FDA):
Cabozantinib. CABOMETYX. 2016, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm497483.htm.
|
|
38
|
Whyte J, Bergin O, Bianchi A, Mcnally S
and Martin F: Key signalling nodes in mammary gland development and
cancer. Mitogen-activated protein kinase signalling in experimental
models of breast cancer progression and in mammary gland
development. Breast Cancer Res. 11:2092009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Javaid S, Zhang J, Smolen GA, Yu M,
Wittner BS, Singh A, Arora KS, Madden MW, Desai R, Zubrowski MJ, et
al: MAPK7 regulates EMT features and modulates the generation of
CTCs. Mol Cancer Res. 13:934–943. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kato Y, Tapping Ri, Huang S, Watson MH,
Ulevitch RJ and Lee JD: Bmk1/Erk5 is required for cell
proliferation induced by epidermal growth factor. Nature.
395:713–716. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kato Y, Kravchenko VV, Tapping RI, Han J,
Ulevitch RJ and Lee JD: BMK1/ERK5 regulates serum-induced early
gene expression through transcription factor MEF2C. EMBO J.
16:7054–7066. 1997. View Article : Google Scholar
|
|
42
|
Dhillon AS, Hagan S, Rath O and Kolch W:
MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Deng X, Yang Q, Kwiatkowski N, Sim T,
McDermott U, Settleman JE, Lee JD and Gray NS: Discovery of a
benzo[e] pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a potent and
selective inhibitor of Big MAP kinase 1. ACS Med Chem Lett.
2:195–200. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yang Q, Deng X, Lu B, Cameron M, Fearns C,
Patricelli MP, Yates JR III, Gray NS and Lee JD: Pharmacological
inhibition of BMK1 suppresses tumor growth through promyelocytic
leukemia protein. Cancer Cell. 18:258–267. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Weygant N, Qu D, Berry WL, May R,
Chandrakesan P, Owen DB, Sureban SM, Ali N, Janknecht R and Houchen
CW: Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent
activity against colorectal and pancreatic cancer through
inhibition of doublecortin-like kinase 1. Mol Cancer. 13:1032014.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Thu KL, Radulovich N, Becker-Santos DD,
Pikor LA, Pusic A, Lockwood WW, Lam WL and Tsao MS: SOX15 is a
candidate tumor suppressor in pancreatic cancer with a potential
role in Wnt/β-catenin signaling. Oncogene. 33:279–288. 2014.
View Article : Google Scholar
|
|
47
|
Qu D, Johnson J, Chandrakesan P, Weygant
N, May R, Aiello N, Rhim A, Zhao L, Zheng W, Lightfoot S, et al:
Doublecortin-like kinase 1 is elevated serologically in pancreatic
ductal adenocar-cinoma and widely expressed on circulating tumor
cells. PLoS One. 10:e01189332015. View Article : Google Scholar
|
|
48
|
Shukla A, Miller JM, Cason C, Sayan M,
MacPherson MB, Beuschel SL, Hillegass J, Vacek PM, Pass HI and
Mossman BT: Extracellular signal-regulated kinase 5: A potential
therapeutic target for malignant mesotheliomas. Clin Cancer Res.
19:2071–2083. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Boguslawski G, Mcglynn PW, Harvey KA and
Kovala AT: SU1498, an inhibitor of vascular endothelial growth
factor receptor 2, causes accumulation of phosphorylated ERK
kinases and inhibits their activity in vivo and in vitro. J Biol
Chem. 279:5716–5724. 2004. View Article : Google Scholar
|
|
50
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M,
Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth,
malignant transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar
|
|
51
|
Yang Q and Lee JD: Targeting the BMK1 MAP
kinase pathway in cancer therapy. Clin Cancer Res. 17:3527–3532.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Sureban SM, May R, Weygant N, Qu D,
Chandrakesan P, Bannerman-Menson E, Ali N, Pantazis P, Westphalen
CB, Wang TC, et al: XMD8-92 inhibits pancreatic tumor xenograft
growth via a DCLK1-dependent mechanism. Cancer Lett. 351:151–161.
2014. View Article : Google Scholar : PubMed/NCBI
|
